on GENFIT (EPA:GNFT)
GENFIT highlights its innovations at the Liver Meeting 2026
GENFIT, a biopharmaceutical company, will participate in the AASLD Liver Meeting 2026. The company will highlight its research on ACLF and the diagnosis of MASH. A scientific event, scheduled for November 8, will detail advances in ACLF treatments with nangibotide. Scientific posters will be presented to discuss the role of inflammation in liver failure. On November 6, a panel of experts will emphasize the importance of non-invasive tests for MASH, which are essential for the early detection of at-risk patients and monitoring their treatment. GENFIT sees these technologies as a way to transform patient care pathways, supported by the NIMBLE and LITMUS consortia.
R. E.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all GENFIT news